Merck’s Emerging Markets R&D Head RuiPing Dong On Developing Drugs To Meet Local Needs: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
Merck discusses its R&D strategy in emerging markets; the company announced last week the largest ever R&D investment in China for a pharmaceutical company.
You may also be interested in...
After announcing the intent to form a partnership a year ago, Merck & Co. announced Sept. 13, a collaboration with BGI (formerly the Beijing Genomics Institute) for discovery and development of biomarkers and genomic technologies
SHANGHAI - Merck & Co. affiliate MSD signed an agreement to form a joint venture July 21 with Simcere Pharmaceutical Group that will see both companies expand access to critical lifestyle drugs across China
Merck Emerging Markets President Kevin Ali On The Branded Generics Business: An Interview With PharmAsia News (Part 2 of 2)
When Merck & Co. Inc. Emerging Markets President Kevin Ali speaks of innovation, it is emblematic of Merck's deep-rooted focus on new drug discovery, but the veteran executive now sees opportunities in the differentiated, branded generics segment. On a recent visit to India, Ali spoke to PharmAsia News' India Bureau about incrementally innovative drugs, access to affordable medicines and also Merck's plans in the BRIC-MT nations.